New research on the use of claims data for gene therapy trials will be presented by HVH Precision Analytics and Diligentia Strategy during the upcoming 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (May 12-15, 2020). This poster presentation will take place virtually during the Cancer – Targeted Gene and Cell Therapy Session on Wednesday, May 13, 2020. The full abstract is now available online.
“We’re excited to show that the application of machine learning approaches, combined with data science expertise and a deep understanding of rare diseases, can accelerate the process of identifying eligible patients for clinical trial recruitment and the launch of new drugs and therapy regimens,” said Oodaye Shukla, Chief Data and Analytics Officer, HVH Precision Analytics. “This, in turn, will lead to faster relief for patients, as well as the ability for HCPs, clinicians, and patient advocacy groups to effectively connect with those who are in need of a medical breakthrough.”
“Drug manufacturers who apply these capabilities to their pipeline programs benefit from targeted real world data with which to accelerate trials and optimally inform commercial strategies,” said Joff Masukawa, President, Diligentia LLC.
Poster Session: Wednesday, May 13, 2020, 5:30 – 6:30 p.m. EDT
Date: Wednesday, May 13, 5:30 – 6:30 p.m. EDT
Title: “The Utility of Claims Data Analysis for Gene Therapy Trials and Commercial Planning” (Abstract #789, page 345)
Click here for more information about the event.